(Q41859467)

13 October 2017

Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines (English)

1 reference

13 October 2017

Jun Zhou

1

1 reference

13 October 2017

Paula Oliveira

2

1 reference

13 October 2017

Xueli Li

3

1 reference

13 October 2017

Zhengming Chen

4

1 reference

13 October 2017

Gerold Bepler

5

1 reference

13 October 2017

28 September 2010

1 reference

13 October 2017

Journal of Nucleic Acids

1 reference

13 October 2017

2010

1 reference

13 October 2017

597098

1 reference

Creative Commons Attribution 3.0 Unported

13 October 2017

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

RRM1-induced metastasis suppression through PTEN-regulated pathways

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Sensitive detection of p53 gene mutations by a 'mutant enriched' PCR-SSCP technique

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952906

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

18 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.4061%2F2010%2F597098

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.4061%2F2010%2F597098

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20976259

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20976259

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4061/2010/597098

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

20976259

1 reference